DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2+mBC

被引：0
|
作者：
Andre, Fabrice
Hamilton, Erika P.
Loi, Sherene
Anders, Carey K.
Schmid, Peter
Stroyakovskiy, Daniil
Villanueva, Rafael
Pedrini, Jose Luiz
Doval, Dinesh Chandra
Zurawski, Bogdan
Chen, Shin-Cheh
Boston, Sarice Renee
Konpa, Adam
Pierotti, Barbara
Fabbri, Giulia
Jhaveri, Komal L.
机构：
[1] Univ Paris Saclay, Gustave Roussy, Villejuif, France
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Peter MacCallum Canc Ctr, Melbourne, Australia
[4] Duke Canc Inst, Durham, NC USA
[5] Queen Mary Univ London, Barts Canc Inst, London, England
[6] Moscow City Oncol Hosp 62, Moscow, Russia
[7] ICO Hosp, Barcelona, Spain
[8] Nossa Senhora Conceicao Hosp, Porto Alegre, Brazil
[9] Rajiv Gandhi Canc Inst & Res Ctr, New Delhi, India
[10] F Lukaszczyk Oncol Ctr, Bydogoszcz, Poland
[11] Linkou Chang Gung Mem Hosp, Dept Gen Surg & Breast Surg, Taoyuan, Taiwan
[12] AstraZeneca, Gaithersburg, MD USA
[13] AstraZeneca, Warsaw, Mazowieckie, Poland
[14] AstraZeneca, Boston, MA USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1009
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Kolberg, Hans-Christian
    Andre, Fabrice
    Hamilton, Erika
    Loi, Sherene
    Schmid, Peter
    Anders, Carey
    Yu, Tinghui
    Boston, Sarice
    D'cruz, Celina
    Herbolsheimer, Pia
    Jhaveri, Komal
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 32 - 32
  • [2] Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).
    Andre, Fabrice
    Hamilton, Erika P.
    Loi, Sherene
    Schmid, Peter
    Anders, Carey K.
    Yu, Tinghui
    Boston, Sarice
    D'Cruz, Celina M.
    Herbolsheimer, Pia
    Jhaveri, Komal L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Andre, Fabrice
    Hamilton, Erika
    Loi, Sherene
    Schmid, Peter
    Yu, Tinghui
    Lu, Shiyao
    Boston, Sarice
    D'Cruz, Celina
    Herbolsheimer, Pia
    Jhaveri, Komal
    CANCER RESEARCH, 2021, 81 (04)
  • [4] A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer
    Hsieh, Y. Pei
    ANNALS OF ONCOLOGY, 2024, 35 : S1394 - S1394
  • [5] Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
    Guarneri, Valentina
    Coelho, Jose Luis Passos
    Duhoux, Francois P.
    Egle, Daniel
    Garcia-Saenz, Jose angel
    Penault-Llorca, Frederique
    Selander, Katri
    Wildiers, Hans
    Zaman, Khalil
    Laeis, Petra
    Lucerna, Markus
    Pierga, Jean-Yves
    FUTURE ONCOLOGY, 2024, 20 (18) : 1237 - 1250
  • [6] Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
    Janjigian, Yelena Y.
    Oh, Do-Youn
    Rha, Sun Young
    Lee, Keun Wook
    Steeghs, Neeltje
    Chao, Yee
    Di Bartolomeo, Maria
    Garcia, Marc Diez
    Mohammad, Nadia Haj
    Stein, Alexander
    McAdoo, William
    Winter, Megan
    Croydon, Liz
    Lee, Jeeyun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)
    Harbeck, Nadia
    Boileau, Jean-Francois
    Modi, Shanu
    Kelly, Catherine M.
    Ohno, Shinji
    Wu, Jiong
    Brekenridge, Mark
    Herbolsheimer, Pia
    Yu, Tinghui
    Pusztai, Lajos
    CANCER RESEARCH, 2022, 82 (04)
  • [8] Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
    Stein, Alexander
    Lordick, Florian
    Janjigian, Yelena Y.
    Oh, Do-Youn
    Lee, Keun-Wook
    Steeghs, Neeltje
    Chao, Yee
    Di Bartolomeo, Maria
    Garcia, Marc Diez
    Mohammad, Nadia Haj
    Mcadoo, William
    Winter, Megan
    Croydon, Elizabeth
    Lee, Jeeyun
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 94 - 94
  • [9] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
    Jerusalem, Guy Heinrich Maria
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Gonzalez, Xavier
    Hall, Peter S.
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R. C.
    Sagara, Yasuaki
    Tokunaga, Eriko
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb C.
    Perrin, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Dose-escalation and Dose-expansion Study of Trastuzumab-deruxtecan(T-Dxd) Monotherapy and Combinations in Patients with advanced/metastatic HER2+Gastric Cancer (GC)/Adenocarcinoma of the gastroesophageal Junction (GEJA): DESTINY-Gastric03
    Lordick, F.
    Janjigian, Y. Y.
    Oh, D. -Y.
    Rha, S. Y.
    Lee, K. -W.
    Steeghs, N.
    Chao, Y.
    Di Bartolomeo, M.
    Diez, Garcia M.
    Haj, Mohammad N.
    Stein, A.
    McAdoo, W.
    Winter, M.
    Croydon, E.
    Lee, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 222 - 222
12345